Novel Small Molecule GLP-1R Agonists
This combination improves the appearance of skin on all fronts it evens out skin tone and reduces signs of aging, providing not only a brightening effect but also a dose of hydration
In 2025, 36% of employers offered to cover GLP-1 drugs as a treatment for both obesity and diabetes, with about 55% covering diabetes alone
Once-weekly GLP2 versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial
The reasons are likely multifactorialdisease complexity, bioavailability, formulation, dosing, and patient selection all matter
Your skin glows naturally when this cycle is healthy